<DOC>
	<DOCNO>NCT00697541</DOCNO>
	<brief_summary>Phase II systemic bioavailability crossover study measure exposure Col-118 topical 0.18 % Facial Gel Brimonidine Ophthalmic Solution 0.2 %</brief_summary>
	<brief_title>Systemic Bioavailability Study Of Col-118 Administered Topically 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2 %</brief_title>
	<detailed_description>A double-blind , randomize , 2-way crossover , safety , pharmacokinetic/-dynamic ( PK/PD ) study 0.18 % COL-118 facial gel 0.2 % brimonidine ophthalmic solution administer male female patient moderate severe erythematous rosacea . Twenty male female subject moderate severe erythematous rosacea randomize 2 group 10 subject . Each group randomize receive 2 treatment ( Treatments A B , Sequence 1 : A/B Sequence 2 : B/A ) , follow : Treatment A : One 1-g application 0.18 % COL-118 facial gel ( 1.8 mg brimonidine ) administer topically plus one drop Advanced Eye Relief™ eye , morning . 1 g 0.18 % COL-118 facial gel reapplied four hour ; Treatment B : One 1-g application COL-118 facial gel vehicle ( 0.0 mg brimonidine tartrate ) administer topically plus one drop 0.2 % brimonidine ophthalmic solution ( 0.1 mg brimonidine tartrate/drop ) eye . Four hour first application 1-g COL-118 facial gel vehicle ( 0.0 mg brimonidine ) administer topically . There least 1-day washout dose administration ( Period 1 Period 2 ) . Blood sample PK analysis brimonidine level collect follow time point Period 1 Period 2 : 0 Hour ( prior dose ) 1 , 2 , 3 , 4 ( prior 2nd dose ) , 5 , 6 , 7 , 8 hour post-dose .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female ≥18 year age Clinical diagnosis rosacea A score ≥ 3 CEAS A score ≥ 3 PSA IOP ≥ 10 mm Hg Nonpregnant nonlactating female History hypersensitivity allergy ingredient study drug , unless approve Investigator Use brimonidine prescription medication within 14 day prior Checkin Use overthecounter ( OTC ) , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin , unless deem acceptable Investigator Use systemic topical steroid apply face 14 day prior Check The use Rx OTC product treatment acne rosacea within 14 day prior check The use isotretinoin within 180 day prior check</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>erythematous rosacea</keyword>
	<keyword>facial gel</keyword>
	<keyword>brimonidine</keyword>
	<keyword>ophthalmic solution</keyword>
</DOC>